[PrL-01]For a brilliant future of therapeutic neurology
Satoshi Kuwabara(Department of Neurology, Graduate School of Medicine, Chiba University, Japan)
64th Annual Meeting of the Japanese Society of Neurology
May 31 - Jun 3, 2023Makuhari Messe
You can search for presentations in this event.
Search
64th Annual Meeting of the Japanese Society of Neurology
May 31 - Jun 3, 2023Makuhari Messe
You can search for presentations in this event.
SearchSearch Results(1,710)
[PL-01-1]ALS: Overview of disease pathogenesis and the introduction of precision therapy
Matthew C. Kiernan(Bushell Chair of Neurology, Brain and Mind Centre; Sydney Medical School, University of Sydney; Royal Prince Alfred Hospital, Sydney, Australia)
[PL-02-1]Neurology in Asia: Practice and education in neuromuscular disorders
Nortina Shahrizaila(University of Malaya, Malaysia)
[AWL-01]Genetic Research in Inherited Neuropathies
Yujiro Higuchi(Department of Neurology, Kagoshima University, Japan)
[AWL-02]PET study to elucidate pathophysiology of neurodegenerative diseases and to promote drug discovery
Hitoshi Shimada1,2,3(1.Department of Functional Neurology & Neurosurgery, Center for Integrated Human Brain Science, Brain Research Institute, Niigata University, Japan, 2.Department of Functional Brain Imaging, Institute for Quantum Medical Science, Institutes for Quantum and Radiological Science and Technology, Japan, 3.Department of Neurology, Chiba University, Japan)
[AW-03]Education on neuromuscular electrodiagnosis and neurological symptomatology
Masahiro Sonoo(Department of Neurology, Teikyo University School of Medicine, Japan)
[HQ-01]Current problems and perspectives of new drug development in the field of neurological diseases
Atsushi Hashizume1,2, Masahisa Katsuno1,2(1.Department of Clinical Research Education, Japan, 2.Department of Neurology, Nagoya Universigy Hospital, Japan)
[HQ-02]The Future Pioneered by Open Innovation: Challenges for Establishing an Ecosystem
Makoto Nagaoka1,2(1.BeiGene Japan GK, Japan, 2.DIA Japan Open Innovation Community, Japan)
[HQ-04]Aim for the fastest development and the highest value
Sonoko Misawa(Department of Neurology, Chiba University graduate School of Medicine, Japan)
[NFS-01-1]The role of TDP-43 in the lipid dysregulation in CNS of ALS
Naohiro Egawa1,2,3(1.Department of Neurology, Kyoto University Graduate School of Medicine, Japan, 2.iPSC-Based Drug Discovery and Development Team, RIKEN BioResource Research Center, Japan, 3.Center for iPS Cell Research and Application (CiRA), Kyoto University, Japan)
[NFS-01-2]Metabolomic analysis of ALS
Masahisa Katsuno1,2(1.Department of Neurology, Nagoya University Graduate School of Medicine, Japan, 2.Department of Clinical Research Education, Nagoya University Graduate School of Medicine, Japan)
[NFS-01-3]Making sense of energy imbalance in ALS
Shyuan T. Ngo(The University of Queensland, Australia)
[NFS-01-4]Deciphering the glial functions of TDP-43
Shuo-Chien Ling1,2(1.National University of Singapore, Singapore, 2.Duke-NUS Medical School, Singapore)
[NFS-02-1]Designer DNA drug therapy for ALS and other TDP-43 proteinopathies
Don Cleveland(University of California, San Diego, USA)
[NFS-02-2]Gene therapy for Parkinson's disease
Shin-ichi Muramatsu1,2(1.Division of Neurological Gene Therapy, Center for Open Innovation, Jichi Medical University, Japan, 2.Center for Gene & Cell Therapy, The Institute of Medical Science, The University of Tokyo, Japan)
[NFS-02-3]Advanced Medicine for ALS
Masashi Aoki, Naoki Suzuki, Tetsuya Akiyama, Hitoshi Warita(Department of Neurology, Tohoku University School of Medicine, Japan)
[NFS-02-4]Development of the Therapeutics for Parkinson Disease targeting alpha synuclein
Kensuke Ikenaka, Aguirre Cesar, Keita Kakuda, Hideki Mochizuki(Osaka University Graduate School of Medicine, Japan)
[NFS-02-5]DNA/RNA heteroduplex oligonucleotides for neurological diseases
Takanori Yokota(Department of Neurology and Neurological Science, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Japan)
[NFS-03-1]Mitochondrial twin proteins CHCHD2 and CHCHD10 as neurodegenerative disease-associated proteins
Yuzuru Imai(Juntendo University Graduate School of Medicine, Japan)
[NFS-03-2]Polyglutamine-mediated neurotoxicity in developmental stages of spinal and bulbar muscular atrophy
Tomoki Hirunagi(Department of Neurology, Nagoya University Graduate School of Medicine, Japan)
[NFS-03-3]DNA damage repair and neurodegeneration
Kyota Fujita1, Hitoshi Okazawa2(1.Research Center for Child Mental Development, Kanazawa University, Japan, 2.Department of Neuropathology, Medical Research Institute, Tokyo Medical and Dental University, Japan)
[NFS-03-5]Expanding the repeat disease world unveiled by repeat-associated non-AUG (RAN) translation
Yoshitaka Nagai1,2(1.Department of Neurology, Kindai University Faculty of Medicine, Japan, 2.Life Science Research Institute, Kindai University, Japan)
[NFS-03-6]Neuroinflammation and neurodegeneration
Hitoshi Okazawa(Department of Neuropathology, Tokyo Medical and Dental University, Japan)
[NFS-04-1]Classification of tauopathies based on tau filament structure
Airi Tarutani1,2(1.University Medical Center Goettingen, Institute of Neuropathology, Germany, 2.Tokyo Metropolitan Institute of Medical Science, Department of Brain and Neurosciences, Japan)
[NFS-04-2]Do tau pathology and TDP-43 pathology have mechanistic links?: a review of human neuropathology
Yuichi Riku1,2(1.Inst. for Med. Sci. Aging, Aichi Med. Univ., Japan, 2.Dept. Neurology, Nagoya Univ., Japan)
[NFS-04-3]Actin-binding protein filamin-A as a driver for tau aggregation in progressive supranuclear palsy
Koyo Tsujikawa1,2, Kentaro Sahashi1, Masahisa Katsuno1,3(1.Department of Neurology, Nagoya University Graduate School of Medicine, Japan, 2.Institute for Advanced Research, Nagoya University, Japan, 3.Department of Clinical Research Education, Nagoya University Graduate School of Medicine, Japan)
[NFS-04-4]Treatment strategies targeting tau in progressive supranuclear palsy
Ikuko Aiba(Department of Neurology, National Hospital Organization Higasinagoya National Hospital, Japan)
[HT-01-1]Gantenerumab in early symptomatic Alzheimers Disease
Janice W. Smith(Roche Products Ltd, UK)
[HT-01-2]TRAILBLAZER-ALZ-4: Comparing donanemab to aducanumab in early, symptomatic Alzheimer's disease
Stephane Epelbaum1, Stephen Salloway2, Elly Lee3, Michelle Papka4, Andrew Pain1, Ena Oru1, Margaret B. Ferguson1, Hong Wang1, Michael Case1, Ming Lu1, Emily C. Collins1, Dawn A. Brooks1, John Sims1(1.Eli Lilly and Company, USA, 2.Department of Neurology and Department of Psychiatry, Alpert Medical School of Brown University; Butler Hospital, USA, 3.Irvine Clinical Research, USA, 4.The Cognitive and Research Center of New Jersey LLC, USA)
[HT-01-3]Development of Therapeutics in Alzheimer's disease
Yasuo Toda(Biogen, Japan)
[HT-01-4]CLARITY AD: A Global Phase 3 Trial of Lecanemab in Early Alzheimer's Disease
Jin Zhou(Eisai, Inc., USA)
[HT-02-1]Development of novel thrombolytic agents using SMTP
Kuniyasu Niizuma1,2,3, Hidenori Endo3, Teiji Tominaga3(1.Department of Neurosurgical Engineering and Translational Neuroscience, Graduate School of Biomedical Engineering, Tohoku University, Japan, 2.Department of Neurosurgical Engineering and Translational Neuroscience, Tohoku University Graduate School of Medicine, Japan, 3.Department of Neurosurgery, Tohoku University Graduate School of Medicine, Japan)
[HT-02-2]Development of an efferocytosis drug for the treatment of cerebral ischemia
Akira Shibuya(Center for Innovative Drug Discovery and Faculty of Medicine, University of Tsukuba, Japan)
[HT-02-3]Targeting the moyamoya disease susceptibility gene RNF213 as a therapeutic strategy for stroke
Masafumi Ihara(Department of Neurology, National Cerebral and Cardiovascular Center, Japan)
[HT-02-4]Development of vaccines in ischemic stroke - Focusing on anti-thrombotic vaccines against S100A9
Munehisa Shimamura1,2(1.Department of Gene & Stem Cell Regenerative Therapy, Osaka University, Japan, 2.Department of Neurology, Osaka University, Japan)
[HT-03-1]The ATXN2 complex as a therapeutic target for spinocerebellar ataxias and ALS
Stefan M M. Pulst(University of Utah, USA)
[HT-03-2]Therapeutic approaches for non-coding repeat expansion diseases
Yoshio Ikeda(Department of Neurology, Gunma University Graduate School of Medicine, Japan)
[HT-03-3]Pathophysiology and therapeutic strategies for spinocerebellar ataxia type 42
Fumiaki Tanaka(Department of Neurology and Stroke Medicine, Yokohama City University Graduate School of Medicine, Japan)
[HT-03-4]Multiple system atrophy: from genetics to clinical trials
Shoji Tsuji1,2, Jun Mitsui2,3(1.International University of Health and Welfare, Japan, 2.Department of Neurology, The University of Tokyo Hospital, Japan, 3.Department of Precision Medicine Neurology, The University of Tokyo, Japan)
[HT-04-1]Brain Inflammation in MS; Should It be B-Cell therapy? From the viewpoint of T cells
Kazumasa Yokoyama1,2(1.Tohsei center for neurological diseases, Japan, 2.Department of Neurology Juntendo University, Japan)
[HT-04-2]Contribution of B cells in MS brain inflammation
Koji Shinoda1,2(1.Department of Neurology, Iizuka Hospital, Japan, 2.Department of Neurology, Kyushu University, Japan)
[HT-04-3]Neuroinflammation as therapeutic targets based on innate immune system
Izumi Kawachi1,2(1.Dept. of Neurology, Brain Research Institute, Niigata University, Japan, 2.Medical Education Center, Niigata University School of Medicine, Japan)
[HT-04-4]Glial CNS inflammation and its treatment
Hideyuki Takeuchi(Department of Neurology and Stroke Medicine, Yokohama City University Graduate School of Medicine, Japan)
[HT-05-1]Synuclein-targeting therapies in PD: what do we know and where are we headed?
Takafumi Hasegawa(Division of Neurology, Department of Neuroscience & Sensory Organs, Tohoku University Graduate School of Medicine, Japan)
[HT-05-2]What triggers Parkinson's disease? Approach from familial form for drug discovery
Yutaka Oji1, Nobutaka Hattori1,2(1.Department of Neurology, Juntendo University School of Medicine, Japan, 2.RIKEN Center for Brain Science, Japan)
[HT-05-3]Updates of disease biomarkers of Parkinson's disease
Chin-Hsien Lin(National Taiwan University Hospital, Taiwan)
[HT-05-4]Issues in clinical trials of disease-modifying therapies for Parkinson's disease
Thomas Foltynie1,2(1.UCL Institute of Neurology, UK, 2.National Hospital for Neurology & Neurosurgery, UK)
[HT-06-1]Toward elucidation of neuropathological basis of bipolar disorder
Tadafumi Kato(Department of Psychiatry and Behavioral Science, Juntendo University Graduate School of Medicine, Japan)
[HT-06-2]Drug transporter study at central nervous system barrier using human postmortem brain
Yasuo Uchida(Graduate School of Biomedical and Health Sciences, Hiroshima University, Japan)
[HT-06-3]Atomic structures of pathological protein filaments in neurodegenerative diseases
Masato Hasegawa(Tokyo Metropolitan Institute of Medical Science, Japan)
1,710 results ( 1 - 50 )
- 1
- ...